| Popis: |
Gulparkha Manalai,1 Asadullah Shirzai,2 Ahmad Khalid Aalemi3 1Department of Obstetrics and Gynecology, Shahrara Teaching Hospital, Kabul University of Medical Sciences, Kabul, Afghanistan; 2Department of Medical Imaging and Radiation Sciences, Kabul University of Medical Sciences, Kabul, Afghanistan; 3Department of Epidemiology, Kabul University of Medical Sciences, Kabul, AfghanistanCorrespondence: Ahmad Khalid AalemiDepartment of Epidemiology, Kabul University of Medical Sciences, Kabul, 1001, AfghanistanTel +93747947581 Email aalemi_100@yahoo.comAbstract: Ovarian hyperstimulation syndrome (OHSS) is an exaggerated response to excess hormones and is also one of the life-threatening iatrogenic complications which is associated with ovulation induction. This syndrome usually occurs in women who receive injectable hormones for the stimulation of egg development in the ovaries. This study describes a rare case of moderate ovarian hyperstimulation syndrome which has been managed and treated with high-dose cabergoline. The patient was diagnosed in the Medical Imaging and Radiation Sciences Department of Kabul University of Medical Sciences and treated in Shahrara Teaching Hospital. A 26-year-old woman was diagnosed with the development of bilateral moderate ovarian hyperstimulation syndrome after receiving clomiphene citrate in dose of 100 mg BID on day 5 of period and Human Chorionic Gonadotropin (HCG) 10,000 units for egg release on day 14 of period. The patient was given a high dose of cabergoline. The dose was adjusted to 1 mg/day for eight days since she was diagnosed with ovarian hyperstimulation syndrome. Consequently, the main outcome of our intervention was complete resolution of OHSS as well as complete recovery of the patient. As a result, it is concluded that the high dose of cabergoline prevents and reduces the occurrence, prolongation, and severity of ovarian hyperstimulation syndrome. However, more assessments through randomized controlled trials regarding the efficacy and safety of cabergoline doses and treatment duration for treatment and preventive purposes are required.Keywords: cabergoline, ovarian hyperstimulation syndrome, assisted reproduction treatment |
